Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT06877624
- Locations
- 🇳🇱
ICON plc. Van Swietenlaan 6, Groningen, Netherlands
A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT06714396
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: QRL-101 Dose ADrug: QRL-101 Dose BDrug: Placebo
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06681441
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT06532396
- Locations
- 🇳🇱
ICON plc. Van Swietenlaan 6, Groningen, Netherlands
A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 88
- Registration Number
- NCT05667779
- Locations
- 🇳🇱
ICON plc. Van Swietenlaan 6, Groningen, Netherlands
- Prev
- 1
- 2
- Next
News
Quiver Bioscience Secures $2.15M NIH Grant to Develop AI-Powered CNS Drug Safety Platform
Quiver Bioscience received a $2.15 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke to develop an integrated platform for predicting safety of CNS-targeted antisense oligonucleotide therapeutics.
QurAlis Reports Promising Phase 1 Data for QRL-101 in ALS and Epilepsy Biomarker Study
• QRL-101 demonstrated a dose-dependent, statistically significant decrease in SDTC, a biomarker linked to ALS disease progression and mortality, with effects approximately 50% greater than the previous Kv7 opener ezogabine. • The clinical trial showed significant impact on epilepsy-related biomarkers, including TMS-EMG intracortical facilitation and EEG spectral power changes, suggesting potential anti-seizure effects without sedation. • QurAlis plans to advance QRL-101 into proof-of-concept studies for both ALS and epilepsy based on the favorable safety profile and promising biomarker data from this healthy volunteer study.